On January 7, 2026, Bright Minds Biosciences Inc. mutually agreed to terminate the Equity Distribution Agreement with Piper Sandler & Co. and Cantor Fitzgerald & Co., effective immediately. This filing is significant as it may impact the company's capital raising strategies.